Kringle Pharma, Inc. (4884.T)
JPY 812.0
(-0.49%)
JPY 812.0
(-0.49%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 69.25 Million JPY | -82.33% |
| 2022 | 391.82 Million JPY | 35.23% |
| 2021 | 289.75 Million JPY | -38.04% |
| 2020 | 467.61 Million JPY | 0.0% |
| 2019 | - JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 18.46 Million JPY | -24.13% |
| 2024 Q1 | 18.69 Million JPY | 5.47% |
| 2024 Q2 | 24.33 Million JPY | 30.22% |
| 2023 Q4 | 17.72 Million JPY | 3.17% |
| 2023 FY | 69.25 Million JPY | -82.33% |
| 2023 Q3 | 17.17 Million JPY | 1.11% |
| 2023 Q1 | 17 Million JPY | -93.92% |
| 2023 Q2 | 16.98 Million JPY | -0.07% |
| 2022 FY | 391.82 Million JPY | 35.23% |
| 2022 Q4 | 279.76 Million JPY | 0.0% |
| 2021 FY | 289.75 Million JPY | -38.04% |
| 2020 FY | 467.61 Million JPY | 0.0% |
| 2019 FY | - JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 4.77 Billion JPY | 98.548% |
| PRISM BioLab Co.,LTD | 112.92 Million JPY | 38.677% |
| GNI Group Ltd. | 26.01 Billion JPY | 99.734% |
| Linical Co., Ltd. | 12.3 Billion JPY | 99.437% |
| Trans Genic Inc. | 13.08 Billion JPY | 99.471% |
| MEDINET Co., Ltd. | 661.54 Million JPY | 89.532% |
| Soiken Holdings Inc. | 5.15 Billion JPY | 98.658% |
| Cytori Cell Research Institute, Inc. | 1.56 Billion JPY | 95.562% |
| AnGes, Inc. | 152.98 Million JPY | 54.734% |
| OncoTherapy Science, Inc. | 610.11 Million JPY | 88.65% |
| Nxera Pharma Co., Ltd. | 12.76 Billion JPY | 99.458% |
| Immuno-Biological Laboratories Co., Ltd. | 816.7 Million JPY | 91.521% |
| NanoCarrier Co., Ltd. | 135.5 Million JPY | 48.896% |
| Carna Biosciences, Inc. | 1.62 Billion JPY | 95.741% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 428.36 Million JPY | 83.834% |
| RaQualia Pharma Inc. | 1.9 Billion JPY | 96.358% |
| Chiome Bioscience Inc. | 682.46 Million JPY | 89.853% |
| Kidswell Bio Corporation | 2.43 Billion JPY | 97.152% |
| PeptiDream Inc. | 28.71 Billion JPY | 99.759% |
| Oncolys BioPharma Inc. | 63.03 Million JPY | -9.854% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | - JPY | -Infinity% |
| Healios K.K. | 121 Million JPY | 42.769% |
| BrightPath Biotherapeutics Co., Ltd. | 72 Thousand JPY | -96080.556% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 39.88 Million JPY | -73.615% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 4.51 Billion JPY | 98.465% |
| FunPep Company Limited | 530 Thousand JPY | -12966.038% |
| Stella Pharma Corporation | 269.49 Million JPY | 74.303% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | 316.81 Million JPY | 78.142% |
| Cuorips Inc. | 23.1 Million JPY | -199.758% |
| K Pharma,Inc. | 1 Billion JPY | 93.075% |
| Takara Bio Inc. | 43.5 Billion JPY | 99.841% |
| ReproCELL Incorporated | 2.42 Billion JPY | 97.146% |
| PhoenixBio Co., Ltd. | 1.71 Billion JPY | 95.963% |
| StemCell Institute Inc. | 2.48 Billion JPY | 97.209% |
| Japan Tissue Engineering Co., Ltd. | 2.51 Billion JPY | 97.246% |
| CellSeed Inc. | 190.13 Million JPY | 63.578% |